The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) hit a new 52-week high and has $37.86 target or 62.00% above today’s $23.37 share price. The 5 months bullish chart indicates low risk for the $1.05B company. The 1-year high was reported on Nov, 9 by Barchart.com. If the $37.86 price target is reached, the company will be worth $651.00M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 227,197 shares traded hands or 33.39% up from the average. Aimmune Therapeutics Inc (NASDAQ:AIMT) has risen 47.96% since April 7, 2016 and is uptrending. It has outperformed by 43.17% the S&P500.
Aimmune Therapeutics Inc (NASDAQ:AIMT) Ratings Coverage
Out of 4 analysts covering Aimmune Therapeutics (NASDAQ:AIMT), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $44 is the highest target while $35 is the lowest. The $39.33 average target is 68.29% above today’s ($23.37) stock price. Aimmune Therapeutics has been the topic of 5 analyst reports since August 31, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating given on Monday, August 31 by Credit Suisse. The rating was initiated by Bank of America on Monday, August 31 with “Buy”. Piper Jaffray initiated the stock with “Overweight” rating in Monday, August 31 report. As per Monday, September 26, the company rating was initiated by JMP Securities. The rating was maintained by Piper Jaffray on Tuesday, November 17 with “Overweight”.
According to Zacks Investment Research, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California.”
More notable recent Aimmune Therapeutics Inc (NASDAQ:AIMT) news were published by: Businesswire.com which released: “Aimmune Therapeutics Announces COO Transition” on October 09, 2015, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on July 12, 2015, Businesswire.com published: “Aimmune Therapeutics Completes and Exceeds North American Enrollment Target …” on September 20, 2016. More interesting news about Aimmune Therapeutics Inc (NASDAQ:AIMT) were released by: Businesswire.com and their article: “Allergen Research Corporation Renamed Aimmune Therapeutics” published on May 27, 2015 as well as Fiercebiotech.com‘s news article titled: “Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101” with publication date: June 18, 2015.
AIMT Company Profile
Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, incorporated on June 24, 2011, is a clinical-stage biopharmaceutical firm developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.